Document is current
Any future updates will be listed below
-
Authors
Verhagen, Johan https://orcid.org/0000-0001-8414-1342
Yusuf, Norkhairin
Smith, Emma L.
Whettlock, Emily M.
Naran, Kerina
Arif, Sefina
Peakman, Mark
-
Funding
Funding for this research was provided by:
UCB Pharma Ltd (Not applicable)
- License Information
-
More Information
Article History
Received: 5 June 2019
Accepted: 7 August 2019
First Online: 14 October 2019
Duality of interest
: ES is an employee of UCB Pharma Ltd. who were developing peptide immunotherapy for type 1 diabetes between 2014 and 2018 through a licence agreement with King’s College London. MP is employed by King’s College London and during the period specified received research funds and provided consultancy services for UCB. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
